Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 5 December 2025 - 8 December 2025

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something they’ve been waiting on for years: early clinical proof that Recursion’s AI‑driven platform might actually work in real patients. GlobeNewswire…
8 December 2025
····
SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

Market data in this article are as of December 8, 2025, 09:13 UTC. Where SLS Stock Stands Today SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is trading at around $1.74 per share in early trading on December 8, 2025, barely changed from the previous close. The company’s profile today looks roughly like this: That backdrop sets the stage for today’s…
8 December 2025
····
Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (NASDAQ: GILD) heads into Monday’s session riding an event‑packed weekend: new cancer data at the ASH 2025 hematology meeting, fresh institutional‑ownership filings, and another round of valuation work from analysts and quant platforms. Here’s what investors should know about Gilead Sciences stock before the U.S. market opens on Monday, December 8, 2025. 1. Price action: defensive biotech near…
8 December 2025
···
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Updated: December 7, 2025 – For informational purposes only, not investment advice. 1. VRTX stock snapshot as of early December 2025 Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX shares finished around $455.48, giving the company a market value in the $115–117 billion range. Stock Titan Key numbers investors…
7 December 2025
···
CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics AG (NASDAQ: CRSP) is finishing 2025 in classic high‑beta biotech fashion: big science, big headlines, and big disagreement about where the stock goes next. As of the last U.S. trading session on Friday, 5 December 2025, CRSP changed hands at about $56.88 per share, implying a market value just under $5.9 billion. The stock sits well above its…
7 December 2025
··
INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Published: December 7, 2025 Inovio Pharmaceuticals (NASDAQ: INO) has quietly turned 2025 into a make‑or‑break year. The small‑cap biotech has completed a Biologics License Application (BLA) for its lead DNA immunotherapy INO‑3107, raised fresh capital through two stock offerings, and attracted a flurry of new analyst ratings and algorithmic “Strong Buy” labels — all while still burning cash and generating…
7 December 2025
····
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna Inc. (NASDAQ: MRNA) is back in the spotlight. After months of pressure from collapsing COVID‑19 vaccine demand and rising regulatory scrutiny, the stock has staged a sharp rebound in early December 2025 — powered by a major long‑term safety study from France and a new $1.5 billion credit facility. Here’s a deep dive into the latest news, forecasts, and…
6 December 2025
···
Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

As of the close on Friday, December 5, 2025, Ocular Therapeutix, Inc. (NASDAQ: OCUL) finished regular trading at $12.58 per share, up about 1.2% on the day, with after‑hours quotes on some platforms briefly touching the $14 area. StockAnalysis The move caps a strong week: on Thursday the stock jumped roughly 12.3% to around $12.87, well above its recent averages,…
6 December 2025
····
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna, Inc. (NASDAQ: MRNA) closed today as one of the more talked‑about healthcare names on Wall Street, with the stock rebounding sharply after a bruising year of falling COVID-19 vaccine sales, pipeline setbacks, and rising regulatory risk. Today’s move comes as investors digest a huge, real‑world French study supporting the long‑term safety and effectiveness of mRNA COVID vaccines, fresh details…
5 December 2025
····
Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Published: December 5, 2025 Key Takeaways This article summarizes the latest news, forecasts, and analyses on Aditxt, Inc. (NASDAQ: ADTX) as of December 5, 2025, based on regulatory filings, company press releases and market data. It is informational only and not investment advice. ADTX Stock Price Today: Tiny Float, Huge Swings As of mid‑day U.S. trading on December 5, 2025,…
5 December 2025
····
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc Ltd. (NASDAQ: SPRC) is back on traders’ radar after a frenetic week of news that spans quantum bio‑data analytics, medical endoscopy devices and ongoing restructuring of its biotech portfolio. As of Friday, December 5, 2025, SciSparc shares are trading around $1.79–$1.80, after an early pre‑market jump of about 19% to $2.10, on volume that has already surged well above…
5 December 2025
···
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical, Inc. (NYSE American: PMI) just staged one of the most dramatic moves on Wall Street, with its stock surging more than 80% on December 4, 2025, after the company released new data on its next‑generation artificial heart. Investors are now asking a simple question: is this the start of a longer rerating, or just another spike in a…
5 December 2025
····
1 … 12 13 14 15 16 … 25

Stock Market Today

  • Canaccord Genuity Raises Celestica Price Target to $430, Signals Strong Upside Potential
    February 2, 2026, 3:18 PM EST. Canaccord Genuity Group raised Celestica's (NYSE:CLS) price target from $400 to $430, maintaining a buy rating and implying a 49.5% upside from current levels. Other analysts show mixed sentiment: 15 Buy ratings, four Hold, with a consensus target near $357. Celestica shares traded at $287.63, below its 50-day average of $311.11 but above its 200-day average of $268.07. The company's market cap is $33.1 billion, with a price-to-earnings ratio of 40.13 and beta of 1.86, indicating moderate volatility. Institutional interest has increased, with multiple funds adding to positions, reflecting growing confidence in Celestica's outlook amid a technology sector recovery.
Go toTop